NSABP B-35

这个子项目是许多利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 这项III期、随机、双盲研究将评价阿那曲唑与他莫昔芬相比，在接受乳房肿瘤切除术和乳腺放疗的原发性导管内癌（DCIS）绝经后女性中预防乳腺癌（局部、区域和远处复发，以及对侧乳腺癌）后续发生的有效性。 此外，本研究还将比较辅助性阿那曲唑与他莫昔芬在浸润性乳腺癌、同侧复发、对侧乳腺癌、其他非乳腺第二原发癌、骨质疏松性骨折、无病生存和总生存时间方面的差异。 此外，B-35将确定与他莫昔芬相比，阿那曲唑对患者症状和生活质量的影响。 分析将包括一个基于生存时间的终点，根据所经历的生活质量进行调整。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This Phase III randomized, double-blind study will evaluate the effectiveness of anastrozole compared to tamoxifen in preventing the subsequent occurrence of breast cancer (local, regional and distant recurrences, and contralateral breast cancer) in postmenopausal women with primary ductal carcinoma in situ (DCIS) treated with lumpectomy and breast radiation. In addition, this study will compare adjuvant anastrozole to tamoxifen in terms of time to invasive breast cancer, ipsilateral recurrence, contralateral breast cancer, other non-breast second primary cancers, osteoporotic fractures, disease-free survival, and overall survival. Also, B-35 will ascertain the effects of anastrozole on patients' symptoms and quality of life as compared to tamoxifen. Analysis will include an endpoint based on survival time adjusted for the quality of life experienced.